Saliha Majdoul

Saliha Majdoul

Auto-generated profile, based on publicly available information

Saliha Majdoul

Center for Cancer Research, National Cancer Institute, Frederick, MD, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2021 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
SMSaliha Majdoul
Saliha Majdoul
ACAlex Compton
Alex Compton

28 October 2020 in eLife
Verified
Journal Article
Open access
KRKazi Rahman
Kazi Rahman
CCCharles A Coomer
Charles A Coomer
SMSaliha Majdoul
Saliha Majdoul
SDSelena Y Ding
Selena Y Ding
SPSergi Padilla-Parra
Sergi Padilla-Parra
ACAlex Compton
Alex Compton
The interferon-inducible transmembrane (IFITM) proteins belong to the Dispanin/CD225 family and inhibit diverse virus infections. IFITM3 reduces membrane fusion between cells and virions through a poorly characterized mechanism. Mutation of proline-rich transmembrane protein 2 (PRRT2), a regulator of neurotransmitter release, at glycine-305 was previously linked to paroxysmal neurological disorders in humans. Here, we show that glycine-305 and the homologous site in IFITM3, glycine-95, drive protein oligomerization from within a GxxxG motif. Mutation of glycine-95 (and to a lesser extent, glycine-91) disrupted IFITM3 oligomerization and reduced its antiviral activity against Influenza A virus. An oligomerization-defective variant was used to reveal that IFITM3 promotes membrane rigidity in a glycine-95-dependent and amphipathic helix-dependent manner. Furthermore, a compound which counteracts virus inhibition by IFITM3, Amphotericin B, prevented the IFITM3-mediated rigidification of membranes. Overall, these data suggest that IFITM3 oligomers inhibit virus-cell fusion by promoting membrane rigidity.

15 December 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
GSGuoli Shi
Guoli Shi
ACAbhilash I. Chiramel
Abhilash I. Chiramel
TLTiansheng Li
Tiansheng Li
KLKin Kui Lai
Kin Kui Lai
AKAdam D. Kenney
Adam D. Kenney
ACAlex Compton
Alex Compton
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in immunocompromised individuals is associated with prolonged virus shedding and evolution of viral variants. Rapamycin and its analogs (rapalogs, including everolimus, temsirolimus, and ridaforolimus) are FDA approved as mTOR inhibitors for the treatment of human diseases, including cancer and autoimmunity. Rapalog use is commonly associated with an increased susceptibility to infection, which has been traditionally explained by impaired adaptive immunity. Here, we show that exposure to rapalogs increased susceptibility to SARS-CoV-2 infection in tissue culture and in immunologically naive rodents by antagonizing the cell-intrinsic immune response. We identified 1 rapalog (ridaforolimus) that was less potent in this regard and demonstrated that rapalogs promote spike-mediated entry into cells, by triggering the degradation of the antiviral proteins IFITM2 and IFITM3 via an endolysosomal remodeling program called microautophagy. Rapalogs that increased virus entry inhibited mTOR-mediated phosphorylation of the transcription factor TFEB, which facilitated its nuclear translocation and triggered microautophagy. In rodent models of infection, injection of rapamycin prior to and after virus exposure resulted in elevated SARS-CoV-2 replication and exacerbated viral disease, while ridaforolimus had milder effects. Overall, our findings indicate that preexisting use of certain rapalogs may elevate host susceptibility to SARS-CoV-2 infection and disease by activating lysosome-mediated suppression of intrinsic immunity.

11 April 2025 in Cell
Verified
Journal Article
Closed access
TKTaisuke Kondo
Taisuke Kondo
FBFrançois X.P. Bourassa
François X.P. Bourassa
SASooraj Achar
Sooraj Achar
JDJustyn DuSold
Justyn DuSold
PCPablo F. Céspedes
Pablo F. Céspedes
NTNaomi Taylor
Naomi Taylor

3 October 2025 in Science Advances
Verified
Journal Article
Open access
MAMahesh Agarwal
Mahesh Agarwal
KLKin Kui Lai
Kin Kui Lai
IWIsaiah Wilt
Isaiah Wilt
SMSaliha Majdoul
Saliha Majdoul
AJAbigail A. Jolley
Abigail A. Jolley
ACAlex Compton
Alex Compton
The viral accessory protein Nef is a major determinant of HIV-1 pathogenicity in vivo. Nef is a multifunctional, immunomodulatory protein that downmodulates cell surface proteins, including CD4 and MHC class I (MHC-I), which are important for T cell–mediated immunity. In addition, Nef also regulates cell-intrinsic immunity—Nef boosts the infectivity of virions produced and released from HIV-infected cells, at least in part, by counteracting the antiviral activity of transmembrane proteins SERINC3 and SERINC5. Here, we show that Nef proteins derived from many primary isolates of HIV-1 restore infectivity in interferon-treated cells and confer resistance to the antiviral protein interferon-induced transmembrane protein 3 (IFITM3) in a SERINC3/5-independent manner. Using Nef derived from primary HIV-1 clade C infection, we found that Nef interacts with IFITM3 in membranes, reduces IFITM3 incorporation into HIV-1 virions, and restores HIV-1 fusion with target cells. Our findings reveal a previously unrecognized immunomodulatory role for Nef in the setting of the interferon-induced antiviral state during HIV-1 infection.